353 related articles for article (PubMed ID: 19357643)
1. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
Wirtz PW; Verschuuren JJ; van Dijk JG; de Kam ML; Schoemaker RC; van Hasselt JG; Titulaer MJ; Tjaden UR; den Hartigh J; van Gerven JM
Clin Pharmacol Ther; 2009 Jul; 86(1):44-8. PubMed ID: 19357643
[TBL] [Abstract][Full Text] [Related]
2. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.
Oh SJ; Claussen GG; Hatanaka Y; Morgan MB
Muscle Nerve; 2009 Nov; 40(5):795-800. PubMed ID: 19722254
[TBL] [Abstract][Full Text] [Related]
3. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.
McEvoy KM; Windebank AJ; Daube JR; Low PA
N Engl J Med; 1989 Dec; 321(23):1567-71. PubMed ID: 2555713
[TBL] [Abstract][Full Text] [Related]
4. Treatment for Lambert-Eaton myasthenic syndrome.
Keogh M; Sedehizadeh S; Maddison P
Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260
[TBL] [Abstract][Full Text] [Related]
5. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
Quartel A; Turbeville S; Lounsbury D
Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
[TBL] [Abstract][Full Text] [Related]
6. Treatment in Lambert-Eaton myasthenic syndrome.
Maddison P
Ann N Y Acad Sci; 2012 Dec; 1275():78-84. PubMed ID: 23278581
[TBL] [Abstract][Full Text] [Related]
7. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
Wirtz PW; Titulaer MJ; Gerven JM; Verschuuren JJ
Expert Rev Clin Immunol; 2010 Nov; 6(6):867-74. PubMed ID: 20979551
[TBL] [Abstract][Full Text] [Related]
8. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.
Lundh H; Nilsson O; Rosén I; Johansson S
Acta Neurol Scand; 1993 Aug; 88(2):136-40. PubMed ID: 8213058
[TBL] [Abstract][Full Text] [Related]
9. [Successful treatment of a Lambert-Eaton myasthenic syndrome patient with 3,4-diaminopyridine].
Matsushima M; Yaguchi H; Kishimoto R; Tsuji S; Yabe I; Sasaki H; Nakadate M; Shiraishi H; Motomura M
Nihon Naika Gakkai Zasshi; 2007 Aug; 96(8):1709-11. PubMed ID: 17802724
[No Abstract] [Full Text] [Related]
10. 3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.
Lee MK; Sunwoo IN; Kim SM
J Clin Neurosci; 2018 Apr; 50():194-198. PubMed ID: 29402568
[TBL] [Abstract][Full Text] [Related]
11. Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J
Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of Lambert-Eaton syndrome with 3,4- diaminopyridine and pyridostigmine].
Yachachi Monfort A; Cortés Pastor F; de la Rubia Nieto A; Sánchez Garre MJ
Farm Hosp; 2007; 31(4):254-6. PubMed ID: 18052623
[No Abstract] [Full Text] [Related]
13. Long-term observation of incremental response and antibodies to voltage-gated calcium channels in patients with Lambert-Eaton myasthenic syndrome: two case reports.
Schneider I; Kornhuber ME; Hanisch F
J Med Case Rep; 2015 Mar; 9():59. PubMed ID: 25885033
[TBL] [Abstract][Full Text] [Related]
14. [The treatment of the Eaton-Lambert myasthenic syndrome with 3,4-diaminopyridine].
Casanova B; Vílchez JJ; Rubio P
Rev Clin Esp; 1993 Apr; 192(7):354-5. PubMed ID: 8388576
[No Abstract] [Full Text] [Related]
15. Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J
Cochrane Database Syst Rev; 2005 Apr; (2):CD003279. PubMed ID: 15846654
[TBL] [Abstract][Full Text] [Related]
16. Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome.
Oh SJ; Kim DS; Head TC; Claussen GC
Muscle Nerve; 1997 Sep; 20(9):1146-52. PubMed ID: 9270671
[TBL] [Abstract][Full Text] [Related]
17. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
Newsom-Davis J
Semin Neurol; 2003 Jun; 23(2):191-8. PubMed ID: 12894384
[TBL] [Abstract][Full Text] [Related]
18. Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.
Oh SJ; Shcherbakova N; Kostera-Pruszczyk A; Alsharabati M; Dimachkie M; Blanco JM; Brannagan T; Lavrnić D; Shieh PB; Vial C; Meisel A; Komoly S; Schoser B; Sivakumar K; So Y;
Muscle Nerve; 2016 May; 53(5):717-25. PubMed ID: 26852139
[TBL] [Abstract][Full Text] [Related]
19. [Lambert-Eaton myasthenic syndrome: response to treatment with 3,4-diaminopyridine].
Morata C; Alfaro A; Chumillas MJ; Montalar J
Med Clin (Barc); 1995 Feb; 104(4):156. PubMed ID: 7898163
[No Abstract] [Full Text] [Related]
20. 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.
Molgó J; Guglielmi JM
Pflugers Arch; 1996; 431(6 Suppl 2):R295-6. PubMed ID: 8739381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]